Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drinabant - Opiant Pharmaceuticals

Drug Profile

Drinabant - Opiant Pharmaceuticals

Alternative Names: AVE 1625; OPNT-004

Latest Information Update: 15 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Opiant Pharmaceuticals; sanofi-aventis
  • Class Antidementias; Antipsychotics; Halogenated hydrocarbons; Obesity therapies; Small molecules; Sulfonamides
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Substance-related disorders
  • Discontinued Alzheimer's disease; Obesity; Parkinson's disease; Schizophrenia; Type 2 diabetes mellitus

Most Recent Events

  • 21 Mar 2019 Opiant Pharmaceuticals plans a clinical trial for Substance-related disorders (Acute cannabinoid overdose) in 2020
  • 21 Feb 2019 Early research in Substance-related disorders in USA (Parenteral) prior February 2019
  • 26 Dec 2018 Opiant Pharmaceuticals in-licenses drinabant from Sanofi for the development and commercialisation for Opioid abuse (Acute cannabinoid overdose)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top